There is a great deal of variability in how a patient responds to medications due to the genes that govern drug metabolism, and this can therefore impact drug efficacy. Pharmacogenomics empowers the doctor to provide specific medical interventions, based on the patient’s genetic profile, and replaces the current trial and error approach to drug therapy

mycardioRx analyses genetic variants that affect the metabolism of cardiovascular medications such as:

  • Angiotensin II Receptor Antagonists
  • Antianginal Agents
  • Antiarrhythmics
  • Anticoagulants
  • Antiplatelets
  • Beta Blockers
  • Diuretics
  • Statins


Click here for the full list of medications reported on in mycardioRx


The benefits of pharmacogenomic testing include

  • Improve efficacy of treatment, improved quality of life for the patient
  • Decrease treatment time
  • Save money on ineffective medications
  • Patients avoid unpleasant or possible fatal side effects of some medications